Person:
KOCAKAYA, DERYA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KOCAKAYA

First Name

DERYA

Name

Filters

2009 - 200912020 - 20234
Reset filters

Settings

Author: ERYÜKSEL, SEMİHA EMEL × Subject: Health Sciences ×

Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    PublicationOpen Access
    Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients— case series
    (2022-01-01) AKSOY, AYSUN; BOZKURTLAR, EMİNE; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; İNANÇ, GÜZİDE NEVSUN; KOCAKAYA, DERYA; AKSOY A., KOCAKAYA D., Yalçinkaya Y., BOZKURTLAR E., KARAKURT S., Eryüksel E., İnanç N.
    © TÜBİTAK.Background/aim: Rheumatoid pulmonary nodule can be detected in up to 32% of rheumatoid arthritis (RA) patients and approximately one-third of nodules may cavitate. We aimed to evaluate characteristics of patients with RA developing cavitary pulmonary nodular (CPN) lesions under disease-modifying antirheumatic drugs (DMARDs), follow-up of both cavitary and solid nodules, and their outcome with the treatment. Materials and methods: RA patients who presented with CPN lesions during follow-up were recruited retrospectively in this case series analysis. Total numbers and mean diameters of cavitary and solid nodules in each thorax computed tomography (CT) have been determined and followed up by two experienced pulmonary physicians. Moreover, changes in treatment after the development of the CPN lesions and characteristics of cavitary nodules were collected. Results: Eleven patients with CPN lesions were reported. At the time of CPN diagnosis, more patients were taking leflunomide than methotrexate (81% vs 19%). Half of the patients were receiving biologic therapy and only 18% were taking anti-TNF drugs. After a median of 24 (3–65) months of follow-up, the regression of CPN lesions was determined in 45% (5/11) of patients. Four of these 5 (80%) patients were switched to a treatment regimen without leflunomide and three of them to nonanti-TNF biologic treatment or targeted synthetic DMARDs (tocilizumab, tofacitinib, and rituximab). Conclusion: CPN lesions seen in RA patients are often pulmonary manifestations of the underlying disease; however, one must rule out malignancies or infections. If lesions progress under DMARDs, it is advised to discontinue synthetic DMARDs (LEF/MTX) and switch to another biological DMARD with different modes of action.
  • Thumbnail Image
    PublicationOpen Access
    The role of procalcitonin as a biomarker for acute pulmonary exacerbation in subjects with cystic fibrosis and non-cystic fibrosis bronchiectasis
    (2022-01-01) KOCAKAYA, DERYA; ARIKAN, HÜSEYİN; ERYÜKSEL, SEMİHA EMEL; CEYHAN, BERRİN; Mammadov F., Olgun Yildizel S., Kocakaya D., ARIKAN H., Cinar C., Eryuksel E., CEYHAN B.
    Objective: Patients with cystic fibrosis (CF) and non-CF bronchiectasis are prone to exacerbations of pulmonary infections. C-reactive protein (CRP) and procalcitonin (PCT) are inflammatory markers. The aim of this study is to evaluate the role of CRP and PCT on exacerbations of CF and non-CF bronchiectasis. Patients and Methods: The medical records of 18 CF (52 hospitalizations) and 20 non-CF bronchiectasis patients (51 hospitalizations) were reviewed retrospectively. CRP, PCT levels and, white blood cell (WBC) counts on admission and follow-up were evaluated. Results: C-reactive protein levels correlated with PCT levels on admission in all patients. Baseline PCT levels were markedly higher (>0.5µg/L) in 12% of CF and 10% of non-CF bronchiectasis patients, however, baseline CRP values were markedly higher (>5mg/L) in 96% of CF and non-CF bronchiectasis patients (p=0.760 and p=0.100, respectively). Baseline CRP and PCT levels were positively correlated with hospitalization length (r=0.501, p=0.001 and r=0.289, p=0.04, respectively) in CF patients, but not in non-CF bronchiectasis. Conclusion: Our study shows the potential utility of these biomarkers to determine the severity of the exacerbation particularly predicting hospitalization length in CF patients. Both biomarkers could be able to guide antibiotic treatment of infective exacerbations in CF and non-CF bronchiectasis patients.
  • No Thumbnail Available
    PublicationMetadata only
    The predictive role of psychological status and disease severity indexes on quality of life among patients with non-CF bronchiectasis
    (2022-01-01) KOCAKAYA, DERYA; OLGUN YILDIZELİ, ŞEHNAZ; ERYÜKSEL, SEMİHA EMEL; CEYHAN, BERRİN; CEYHAN B., Bekir M., KOCAKAYA D., OLGUN YILDIZELİ Ş., ERYÜKSEL S. E.
    OBJECTIVE: Bronchiectasis is a chronic suppurative lung disease that significantly impacts the patients\" quality of life. The aim of this study is to evaluate the relationship between quality of life and patient\"s psychological status and bronchiectasis disease severity indexes in patients with non-cystic fibrosis bronchiectasis. We also aimed to investigate the validity and reliability of Turkish version of Quality of Life Questionnaire-Bronchiectasis (V3.1) in Turkish adult bronchiectatic patients.
  • Thumbnail Image
    PublicationOpen Access
    Malign melanom, endobronşial metastaz
    (2009-04-09) KOCAKAYA, DERYA; OLGUN YILDIZELİ, ŞEHNAZ; ERYÜKSEL, SEMİHA EMEL; ÇELİKEL, ÇİĞDEM; KARAKURT, SAİT; Kocakaya D., Abul Y., Olgun Yıldızeli Ş., Eryüksel S. E., Tosuner Z., Yazıcı Z., Çelikel Ç., Karakurt S.
    Amaç: Malign melanoma melanositlerin malign transfomayonu sonucu gelişir.Pulmoner metastazını pulmoner arterlere ulaşan tümör embolileri yoluyla yapar.Endobronşial yayılımlı malign melonom vakaları sınırlı sayıdadır. Gereç ve Yöntem: Nadir görülen endobronşial yayılım yapmış bronkoskopi ile tanı koyduğumuz vakamızı sunduk. Bulgular: 42 yaşında bayan hasta nefes darlığı şikaye ile başvurdu. 2006 da tanı konan sır a konjenital dev nevüs tanısı mevcu u.5 paket/yıl sigara hikayesi mevcu u. Fizik muayenede bel bölgesinde 25x15 cm boyularında yaklaşık tüm lumbar bölgeyi kaplayan gluteal bölgeye de yayılan dev nevüsü mevcu u. Vücu a özellikle sır a ve saçlı deride birden fazla çok sayıda nevüsler izlendi. Nevüslerde renk değişikliği tariflemiyordu. Sır aki dev nevüste kalınlaşma belir yordu. Solunum sistemi muayenesi doğaldı.Aksiller ele gelen 1x2 cm lik lenfadenopa si mevcu u. PA akciğer grafisinde sol hilar bölgede düzensizlik ve dansite ar şı mevcu u. Toraks BT’de sol üst lobda 40x30 mm kitlesel lezyon mevcu u. Bronkoskopide sol akciğer üst lob girişinde nevüs tarzında siyahımsı mukozadan kabarık endobronşial lezyon izlendi. Alınan bronkoskopik biyopsi, rça ve bronkoalveolar lavaj materyalleri malign melonom ile uyumlu geldi. Sonuç: Malign melanoma bağlı endobronşial metastaz nadirdir. Literatürde 1966-2002 yılları arası yapılmış geniş taramada 204 akciğer dışı kaynaklı endobronşial metastaz vakası saptanmış olup bunları sırasıyla meme(%35), böbrek(%17), kolon ve rektum(%15) oluşturmaktadır.. Deri kanseri vakaları sadece 9 vaka olup , 7’si malign melanom kökenli saptanmış r. Tanıda primer akciğer kanserinden ayırtetmek için bronkoskopi şar r. Malign melannomaya bağlı endobronşial metastazı olgumuzu literatürde nadir görülmEsi nedeniyle sunduk.
  • No Thumbnail Available
    PublicationMetadata only
    Increased D-dimer is associated with disease progression and increased mortality in Turkish COVID-19 patients
    (2023-05-31) MERCANCI, ZEYNEP; ILGIN, CAN; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; BALCAN, MEHMET BARAN; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; Mercanci Z., ILGIN C., Yildizeli S. O., KOCAKAYA D., Balcan B., Sengel B. E., KARAKURT S., Eryuksel E.
    Objective: Coagulopathy is thought to play an important role in the development of severe COVID-19. High D-dimer levels have been reported in Chinese cohort studies. However, ethnicity has significant implications for thrombotic risk. Our aim in this study is to determine the effect of D-dimer measurements on disease prognosis and mortality in Turkish patients with COVID-19. Patients and Methods: The study was designed retrospectively. Patients over the age of 18 who were admitted to our hospital were included in the study. Results: The study included 226 patients. According to the World Health Organization staging, 75(33.2%) patients, according to the staging of Siddiqi et al., 67 (29.7%) patients progressed. In the ROC analysis performed to predict mortality, AUC value for D-dimer was found to be 82.25% (95%CI 74.8%-89.71%). When the cut-off value for D-dimer was accepted as ≥3.25mg/L, specificity was 94.15%, correctly classified rate 88.5%, positive likelihood ratio as (LR):5.69, negative LR:0.71. Conclusion: As a result, similar to the Chinese cohorts, elevated D-dimer measurements increase disease progression and mortality in Turkish patients with COVID-19. D-dimer levels of 3.25 mg/L and above, strongly determine the risk of increased mortality in the Turkish Caucasian ethnic group.